Analysts See $-0.01 EPS for ChromaDex Corporation (CDXC)

February 23, 2018 - By Adrian Erickson

 Analysts See $ 0.01 EPS for ChromaDex Corporation (CDXC)

Analysts expect ChromaDex Corporation (NASDAQ:CDXC) to report $-0.01 EPS on March, 15.They anticipate $0.05 EPS change or 83.33 % from last quarter’s $-0.06 EPS. After having $-0.07 EPS previously, ChromaDex Corporation’s analysts see -85.71 % EPS growth. The stock increased 2.73% or $0.14 during the last trading session, reaching $5.26. About 373,091 shares traded. ChromaDex Corporation (NASDAQ:CDXC) has declined 38.10% since February 23, 2017 and is downtrending. It has underperformed by 54.80% the S&P500.

ChromaDex Corporation, a natural products company, discovers, acquires, develops, and commercializes patented and proprietary ingredient technologies. The company has market cap of $282.97 million. The firm offers bulk raw materials for use in dietary supplements, food, beverages, and cosmetic products; Nicotinamide riboside , a vitamin found naturally in milk for enhancing cardiovascular health, glucose levels, cognitive function, and anti-aging effects; Pterostilbene (pTeroPure), a polyphenol and antioxidant used in health related fields; and Immulina, a spirulina extract and compound, which is used for improving human immune function, as well as developing Pterostilbene and caffeine co-crystal ingredients, and anthocyanins ingredients. It currently has negative earnings. It also provides reference standards, materials, and kits to conduct quality control of raw materials and consumer products; and fine chemicals and phytochemicals for research and new product development applications.

More recent ChromaDex Corporation (NASDAQ:CDXC) news were published by: which released: “ChromaDex Corporation Reports Preliminary 2017 Results” on February 12, 2018. Also published the news titled: “ChromaDex Chairman Stephen Allen Will Retire from Board of Directors” on February 16, 2018.‘s news article titled: “ChromaDex to Present at the 3rd Annual NAD+ Summit” with publication date: January 24, 2018 was also an interesting one.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our FREE daily email newsletter: